2025
The peptidoglycan of Borrelia burgdorferi can persist in discrete tissues and cause systemic responses consistent with chronic illness
McClune M, Ebohon O, Dressler J, Davis M, Tupik J, Lochhead R, Booth C, Steere A, Jutras B. The peptidoglycan of Borrelia burgdorferi can persist in discrete tissues and cause systemic responses consistent with chronic illness. Science Translational Medicine 2025, 17: eadr2955. PMID: 40267217, PMCID: PMC12207536, DOI: 10.1126/scitranslmed.adr2955.Peer-Reviewed Original ResearchConceptsAcute infectionPeripheral blood mononuclear cellsBlood mononuclear cellsMurine modelPostinfectious complicationsMononuclear cellsMinimal pathologyKupffer cellsPersistent symptomsLyme arthritisPublic health concernLiver occupationLiver accumulationInflamed jointsSecreted protein profileInfectionChronic illnessOrgan-specificPatientsSynovial fluidPathogenic molecules
2024
Bridging the gap: strategies for recognizing and managing post-COVID conditions
Khan M, Becker R. Bridging the gap: strategies for recognizing and managing post-COVID conditions. Frontiers In Medicine 2024, 11: 1395420. PMID: 39635598, PMCID: PMC11615723, DOI: 10.3389/fmed.2024.1395420.Peer-Reviewed Original ResearchQuality of lifePost-COVID conditionsTargeted interventionsPrevalence of chronic conditionsStandardized screening toolPatient-centered approachPrevalence of post-COVID conditionImprove quality of lifeHigh-risk individualsPsychosocial healthHealthcare providersChronic conditionsCardiovascular healthEarly diagnosisImprove qualityScreening toolPeripheral vascular diseaseCommunity leadersComorbid conditionsDevelopment of screening strategiesPersistent symptomsCost-effective screening approachHealthAffected individualsInterventionPostacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review
Miller C, Borre C, Green A, Funaro M, Oliveira C, Iwasaki A. Postacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review. American Journal Of Medicine Open 2024, 12: 100078. PMID: 39639960, PMCID: PMC11617896, DOI: 10.1016/j.ajmo.2024.100078.Peer-Reviewed Original ResearchClinical epidemiologyPost-acute sequelae of COVID-19High risk of biasLack of standardized definitionsPost-acute sequelaeRisk of biasSequelae of COVID-19United StatesScoping ReviewComprehensive literature searchUS childrenShort follow-up durationFollow-up durationInclusion criteriaFemale sexOlder ageRisk factorsSARS-CoV-2 infectionLiterature searchChest painHigh riskOptimal preventionPediatric patientsPersistent symptomsCOVID-19Evaluating Ischemic Heart Disease in Women: Focus on Angina With Nonobstructive Coronary Arteries (ANOCA)
Maayah M, Latif N, Vijay A, Gallegos C, Cigarroa N, Martinez E, Mazure C, Miller E, Spatz E, Shah S. Evaluating Ischemic Heart Disease in Women: Focus on Angina With Nonobstructive Coronary Arteries (ANOCA). Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 102195. PMID: 39166160, PMCID: PMC11330936, DOI: 10.1016/j.jscai.2024.102195.Peer-Reviewed Original ResearchIschemic heart diseaseNonobstructive coronary arteriesCoronary artery diseaseArtery diseaseObstructive coronary artery diseaseCoronary arteryLong-term cardiovascular prognosisHeart diseaseSuspected ischemic heart diseaseAtherosclerotic coronary artery diseaseCoronary vasomotor disordersPretest probability of diseasePragmatic diagnostic algorithmExpert consensus documentEvaluating ischemic heart diseaseImpact quality of lifeQuality of lifeSymptomatic patientsPretest probabilityANOCACardiovascular prognosisVasomotor disordersDiagnostic evaluationPersistent symptomsDiagnostic strategiesYouth adversity and trajectories of depression/anxiety symptoms in adolescence in the context of intersectionality in the United Kingdom.
Havers L, Shuai R, Fonagy P, Fazel M, Morgan C, Fancourt D, McCrone P, Smuk M, Bhui K, Shakoor S, Hosang G. Youth adversity and trajectories of depression/anxiety symptoms in adolescence in the context of intersectionality in the United Kingdom. Psychological Medicine 2024, 54: 2677-2687. PMID: 38623689, DOI: 10.1017/s0033291724000795.Peer-Reviewed Original ResearchDepression/anxiety symptomsAnxiety symptomsDevelopment of depressionPersistence of depressionSymptoms of depressionModerating effectContext of intersectionalityIndividual characteristicsLatent trajectoriesAdvantaged groupsSocietal groupsAnxietyDepressionMagnitude of effectAdversityAssociated with persistenceSymptomsModeratelyAdolescentsUnited KingdomIntersecting profilesYouthSESPersistent symptomsIntersectionIron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19
Hanson A, Mulè M, Ruffieux H, Mescia F, Bergamaschi L, Pelly V, Turner L, Kotagiri P, Göttgens B, Hess C, Gleadall N, Bradley J, Nathan J, Lyons P, Drakesmith H, Smith K. Iron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19. Nature Immunology 2024, 25: 471-482. PMID: 38429458, PMCID: PMC10907301, DOI: 10.1038/s41590-024-01754-8.Peer-Reviewed Original ResearchConceptsStress erythropoiesisNumbers of dendritic cellsLow serum ironSARS-CoV-2Long-term outcomesWeek of diseaseIncreased iron demandOutcomes of COVID-19SARS-CoV-2 infectionCOVID-19 symptom onsetCOVID-19 severityDendritic cellsPersistent symptomatologyMonth 1Serum ironProliferating lymphocytesIron homeostasisUnresolved inflammationSymptom onsetPersistent symptomsHospitalized patientsDysregulated erythropoiesisInflammatory disequilibriumLong-term outcomes of COVID-19Iron homeostasis gene expression
2023
Incidence and psychiatric predictors of Long COVID beyond 3 months in a city-wide community sample in Texas
Tsai J, Grace A, Kurian A. Incidence and psychiatric predictors of Long COVID beyond 3 months in a city-wide community sample in Texas. Journal Of Public Health 2023, 46: e51-e59. PMID: 38141051, DOI: 10.1093/pubmed/fdad276.Peer-Reviewed Original ResearchLong COVID symptomsLong COVIDCOVID symptomsDuration of illnessLaboratory-confirmed casesLongitudinal cohort studyLoss of tasteCOVID-19 symptomsBaseline depression symptomsPopulation-based sampleCOVID-19Persistent symptomsCohort studyInverse probability weightingDepression symptomsPsychiatric predictorsWhite adultsSymptomsCoronavirus diseaseGreater riskMonthsAdultsCommunity sampleCOVIDGreater anxietyAnatomic patterns in claudicants who fail supervised exercise therapy
Breen T, McGinigle K, Strosberg D, Dardik A, Altin S. Anatomic patterns in claudicants who fail supervised exercise therapy. Journal Of Vascular Surgery 2023, 79: 679-684.e1. PMID: 37984757, DOI: 10.1016/j.jvs.2023.11.020.Peer-Reviewed Original ResearchCritical limb-threatening ischemiaSupervised exercise therapyPeripheral arterial diseaseIntermittent claudicationCFA diseaseExercise therapyArterial diseaseAnatomic patternsCommon femoral artery diseaseFemoral artery diseaseAnkle-brachial indexLimb-threatening ischemiaSubset of patientsVeterans Health AdministrationPersistent symptomsProgressive diseaseProgressive symptomsArtery diseaseDisease locationPatientsWest HavenHealth AdministrationMultivariate analysisRevascularizationDiseasePersistent symptoms and conditions among children and adolescents hospitalised with COVID-19 illness: a qualitative study
Messiah S, Francis J, Weerakoon S, Mathew M, Shaikh S, Veeraswamy A, Lozano A, He W, Xie L, Polavarapu D, Ahmed N, Kahn J. Persistent symptoms and conditions among children and adolescents hospitalised with COVID-19 illness: a qualitative study. BMJ Open 2023, 13: e069073. PMID: 37734886, PMCID: PMC10514629, DOI: 10.1136/bmjopen-2022-069073.Peer-Reviewed Original ResearchConceptsCOVID-19 illnessIn-depth interviewsQualitative studyPaediatric healthcare systemHealth information sourcesLack of insurance coverageMental health impactsPrevalence of long COVIDPersistent symptomsPost-COVID-19 symptomsPost-traumatic stress disorderPersistent COVID-19 symptomsHealthcare systemCOVID-19 experiencePre-existing conditionsQualitative interviewsInsurance coverageCOVID-19Support strategiesWorsening pre-existing conditionsHealth impactsIllnessSupport systemInterviewsLong COVIDPrevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults — United States, December 2020–March 2023
Montoy J, Ford J, Yu H, Gottlieb M, Morse D, Santangelo M, O’Laughlin K, Schaeffer K, Logan P, Rising K, Hill M, Wisk L, Salah W, Idris A, Huebinger R, Spatz E, Rodriguez R, Klabbers R, Gatling K, Wang R, Elmore J, McDonald S, Stephens K, Weinstein R, Venkatesh A, Saydah S, Group I, Group I, Ahmed Z, Choi M, Derden A, Gottlieb M, Guzman D, Hassaballa M, Jerger R, Kaadan M, Koo K, Yang G, Dorney J, Kinsman J, Li S, Lin Z, Mannan I, Pierce S, Puente X, Ulrich A, Yang Z, Yu H, Adams K, Anderson J, Chang G, Gentile N, Geyer R, Maat Z, Malone K, Nichol G, Park J, Ruiz L, Schiffgens M, Stober T, Willis M, Zhang Z, Amadio G, Charlton A, Cheng D, Grau D, Hannikainen P, Kean E, Kelly M, Miao J, Renzi N, Shughart H, Shughart L, Shutty C, Watts P, Kane A, Nikonowicz P, Sapp S, Gallegos D, Martin R, Chandler C, Eguchi M, L’Hommedieu M, Moreno R, Roldan K, Arreguin M, Chan V, Chavez C, Kemball R, Wong A, Briggs-Hagen M, Hall A, Plumb I. Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults — United States, December 2020–March 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 859-865. PMID: 37561663, PMCID: PMC10415002, DOI: 10.15585/mmwr.mm7232a2.Peer-Reviewed Original ResearchConceptsCOVID-like illnessSARS-CoV-2 test resultsPost-COVID conditionsNegative SARS-CoV-2 test resultsPositive SARS-CoV-2 test resultProspective multicenter cohort studySARS-CoV-2 infectionMulticenter cohort studyPrevalence of symptomsTime of enrollmentCOVID-19 testing statusHealth care providersSARS-CoV-2Self-reported symptomsCohort studyPersistent symptomsAcute illnessAntigen testPolymerase chain reactionClinical signsSymptom progressionCare providersDrug AdministrationTesting statusSymptomsLong COVID Clinical Phenotypes up to 6 Months After Infection Identified by Latent Class Analysis of Self-Reported Symptoms
Gottlieb M, Spatz E, Yu H, Wisk L, Elmore J, Gentile N, Hill M, Huebinger R, Idris A, Kean E, Koo K, Li S, McDonald S, Montoy J, Nichol G, O’Laughlin K, Plumb I, Rising K, Santangelo M, Saydah S, Wang R, Venkatesh A, Stephens K, Weinstein R, Weinstein R, Gottlieb M, Santangelo M, Koo K, Derden A, Gottlieb M, Gatling K, Guzman D, Yang G, Kaadan M, Hassaballa M, Jerger R, Ahmed Z, Choi M, Venkatesh A, Spatz E, Lin Z, Li S, Yu H, Liu M, Venkatesh A, Spatz E, Ulrich A, Kinsman J, Dorney J, Pierce S, Puente X, Nichol G, Stephens K, Anderson J, Morse D, Adams K, Maat Z, Stober T, O’Laughlin K, Gentile N, Geyer R, Willis M, Ruiz L, Malone K, Park J, Rising K, Kean E, Kelly M, Schaeffer K, Hannikainen P, Shughart L, Shughart H, Renzi N, Amadio G, Grau D, Watts P, Cheng D, Miao J, Shutty C, Charlton A, Hill M, Chavez S, Kane A, Nikonowicz P, Idris A, McDonald S, Gallegos D, Martin R, Elmore J, Wisk L, L’Hommedieu M, Chandler C, Eguchi M, Roldan K, Villegas N, Moreno R, Rodrigue R, Wang R, Montoy J, Kemball R, Chan V, Chavez C, Wong A, Arreguin M. Long COVID Clinical Phenotypes up to 6 Months After Infection Identified by Latent Class Analysis of Self-Reported Symptoms. Open Forum Infectious Diseases 2023, 10: ofad277. PMID: 37426952, PMCID: PMC10327879, DOI: 10.1093/ofid/ofad277.Peer-Reviewed Original ResearchThe Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger C. The Pharmacological Treatment of Obsessive-Compulsive Disorder. Psychiatric Clinics Of North America 2023, 46: 107-119. PMID: 36740347, DOI: 10.1016/j.psc.2022.11.005.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPharmacological treatmentOptimal evidence-based treatmentSelective serotonin reuptake inhibitorsFirst-line treatmentSerotonin reuptake inhibitorsMore treatment optionsEvidence-based treatmentsCare of individualsPersistent symptomsReuptake inhibitorsTreatment optionsAppropriate psychotherapySubstantial minorityTreatmentDisordersAugmentation strategiesRobust evidenceEvidentiary supportAntidepressantsPatientsClomipramineSymptomsMainstayFurther work
2022
Is central anticholinergic syndrome linked to opioid use for cervical cancer pain?
Choi A, Bui T, Y. Pan E, Ozcan M. Is central anticholinergic syndrome linked to opioid use for cervical cancer pain? Anaesthesia Pain & Intensive Care 2022, 26: 831-835. DOI: 10.35975/apic.v26i6.2068.Peer-Reviewed Original ResearchCentral anticholinergic syndromeMorphine equivalent doseCancer-related painAnticholinergic syndromeMagnetic resonance imagingOpioid antagonistOpioid useCancer painNeurological symptomsAnticholinergic medicationsWorld Health OrganizationEmergency departmentExposure to anticholinergic medicationsPeripheral neurological symptomsMRI magnetic resonance imagingWHO - World Health OrganizationOpioid exposureAnticholinergic toxicityCase reportPain managementOpioidPersistent symptomsPainIncomplete responseEquivalent doseComparison of Long-Term Complications of COVID-19 Illness among a Diverse Sample of Children by MIS-C Status
Messiah S, Xie L, Mathew M, Shaikh S, Veeraswamy A, Rabi A, Francis J, Lozano A, Ronquillo C, Sanchez V, He W, Weerakoon S, Srikanth N, Borel M, Kapera O, Kahn J. Comparison of Long-Term Complications of COVID-19 Illness among a Diverse Sample of Children by MIS-C Status. International Journal Of Environmental Research And Public Health 2022, 19: 13382. PMID: 36293968, PMCID: PMC9603408, DOI: 10.3390/ijerph192013382.Peer-Reviewed Original ResearchConceptsMIS-CCOVID-19 illnessSevere COVID illnessMultisystem inflammatory syndromeLong symptomsPediatric COVID-19 casesAssociated with SARS-CoV-2 infectionPediatric healthcare systemLong COVIDSARS-CoV-2 infectionRetrospective EHR reviewFollow-up surveyInflammatory syndromePersistent symptomsEthnically diverse childrenPediatric professionalsPresence of long COVIDHealthcare systemVulnerable populationsPost-COVID-19 recovery effortsGovernment insurancePrivate insuranceSymptomsCOVID illnessIllnessLong-Term Complications of COVID-19 Infection in Adolescents and Children
Thallapureddy K, Thallapureddy K, Zerda E, Suresh N, Kamat D, Rajasekaran K, Moreira A. Long-Term Complications of COVID-19 Infection in Adolescents and Children. Current Pediatrics Reports 2022, 10: 11-17. PMID: 35127274, PMCID: PMC8803461, DOI: 10.1007/s40124-021-00260-x.Peer-Reviewed Original ResearchLong COVIDSARS-CoV-2 infectionPersistent COVID-19 symptomsLong COVID-19Long COVID symptomsSymptomatic COVID-19COVID-19 infectionCOVID-19 symptomsHealth care providersCOVID-19Recent FindingsChildrenPersistent symptomsTerm complicationsPediatric populationCOVID symptomsCare providersSymptomsOlder childrenChildrenAdultsInfectionMore evidenceAdolescentsCOVIDPotential effects
2021
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study
Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F, Mazia C, Wilken M, Wilken M, Barroso F, Saba J, Rugiero M, Bettini M, Chaves M, Vidal G, Garcia A, De Bleecker J, Van den Abeele G, Koning K, De Mey K, Mercelis R, Mahieu D, Wagemaekers L, Van Damme P, Depreitere A, Schotte C, Smetcoren C, Stevens O, Van Daele S, Vandenbussche N, Vanhee A, Verjans S, Vynckier J, D'Hont A, Tilkin P, Siqueira Carvalho A, Brockhausen I, Feder D, Ambrosio D, César P, Melo A, Ribeiro R, Rocha R, Rosa B, Veiga T, Silva L, Engel M, Geraldo J, Penha Ananias Morita M, Coelho E, Paiva G, Pozo M, Prando N, Torres D, Butinhao C, Duran G, Fialho T, Silva T, Gonçalves L, Pazetto L, Volpe L, Duca L, Friedrich M, Guerreiro A, Mohr H, Martins M, Cruz Pacheco D, Ferreira L, Macagnan A, Pinto G, Cassia Santos A, Oliveira A, Andrade A, Annes M, Silva L, Lino V, Pinto W, Assis N, Carrara F, Miranda C, Souza I, Fernandes P, Phan C, Narayan J, Blackmore D, Mallon A, Roderus R, Watt E, Vohanka S, Bednarik J, Chmelikova M, Cierny M, Toncrova S, Junkerova J, Kurkova B, Reguliova K, Zapletalova O, Pitha J, Novakova I, Tyblova M, Jurajdova I, Wolfova M, Andersen H, Harbo T, Vinge L, Krogh S, Mogensen A, Vissing J, Højgaard J, Witting N, Autzen A, Pedersen J, Erälinna J, Laaksonen M, Oksaranta O, Harrison T, Eriksson J, Rozsa C, Horvath M, Lovas G, Matolcsi J, Szabo G, Jakab G, Szabadosne B, Vecsei L, Dezsi L, Varga E, Konyane M, Antonini G, Di Pasquale A, Garibaldi M, Morino S, Troili F, Fionda L, Di Pasquale A, Garibaldi M, Saccà F, Filla A, Costabile T, Marano E, Fasanaro A, Marsili A, Puorro G, Mantegazza R, Antozzi C, Bonanno S, Camera G, Locatelli A, Maggi L, Pasanisi M, Campanella A, Evoli A, Alboini P, D'Amato V, Iorio R, Inghilleri M, Fionda L, Frasca V, Giacomelli E, Gori M, Lopergolo D, Onesti E, Frasca V, Gabriele M, Uzawa A, Kanai T, Kawaguchi N, Mori M, Kaneko Y, Kanzaki A, Kobayashi E, Murai H, Masaki K, Matsuse D, Matsushita T, Uehara T, Shimpo M, Jingu M, Kikutake K, Nakamura Y, Sano Y, Utsugisawa K, Nagane Y, Kamegamori I, Tsuda T, Fujii Y, Futono K, Ozawa Y, Mizugami A, Saito Y, Samukawa M, Suzuki H, Morikawa M, Kamakura S, Miyawaki E, Shiraishi H, Miyazaki T, Motomura M, Mukaino A, Yoshimura S, Asada S, Yoshida S, Amamoto S, Kobashikawa T, Koga M, Maeda Y, Takada K, Takada M, Tsurumaru M, Yamashita Y, Yoshida S, Suzuki Y, Akiyama T, Narikawa K, Tano O, Tsukita K, Kurihara R, Meguro F, Fukuda Y, Sato M, Okumura M, Funaka S, Kawamura T, Nakamori M, Takahashi M, Taichi N, Hasuike T, Higuchi E, Kobayashi H, Osakada K, Imai T, Tsuda E, Shimohama S, Hayashi T, Hisahara S, Imai T, Kawamata J, Murahara T, Saitoh M, Shimohama S, Suzuki S, Yamamoto D, Ishiyama Y, Ishiyama N, Noshiro M, Takeyama R, Uwasa K, Yasuda I, Kim B, Lee C, Koo Y, Seok H, Kang H, Ra H, Kim B, Cho E, Choi M, Lee H, Min J, Seok J, Lee J, Koh D, Kwon J, Park S, Choi E, Hong Y, Ahn S, Koo D, Lim J, Shin C, Hwang J, Kim M, Kim S, Jeong H, Jung J, Kim Y, Lee H, Shin H, Hwang E, Shin M, Kooi A, Visser M, Gibson T, Casasnovas C, Aguilo M, Homedes‐Pedret C, Palacios N, Porras L, Santamaria V, Lazaro A, Tejedor E, Salcedo P, Fernandez‐Fournier M, Ruiz P, Rivera F, Fernandez‐Fournier M, Sastre M, Carbonell J, Sune P, Figueras M, Gili G, Mazuela G, Illa I, Vicente E, Diaz‐Manera J, Gutiérrez L, Garcia R, Vidal N, Arribas‐Ibar E, Piehl F, Hietala A, Bjarbo L, Sengun I, Meherremova A, Ozcelik P, Balkan B, Tuga C, Ugur M, Erdem‐Ozdamar S, Bekircan‐Kurt C, Acar N, Yilmaz E, Caliskan Y, Orsel G, Efendi H, Aydinlik S, Cavus H, Kutlu A, Becerikli G, Semiz C, Tun O, Terzi M, Dogan B, Onar M, Sen S, Cavdar T, Veske A, Norwood F, Dimitriou A, Gollogly J, Mahdi‐Rogers M, Seddigh A, Sokratous G, Maier G, Sohail F, Jacob S, Sadalage G, Torane P, Brown C, Shah A, Sathasivam S, Arndt H, Davies D, Watling D, Amato A, Cochrane T, Salajegheh M, Roe K, Amato K, Toska S, Wolfe G, Silvestri N, Patrick K, Zakalik K, Katz J, Miller R, Engel M, Forshew D, Bravver E, Brooks B, Sanjak M, Plevka S, Burdette M, Cunningham S, Sanjak M, Kramer M, Nemeth J, Schommer C, Scott T, Juel V, Guptill J, Hobson‐Webb L, Massey J, Beck K, Carnes D, Loor J, Anderson A, Pascuzzi R, Bodkin C, Kincaid J, Snook R, Guingrich S, Micheels A, Chaudhry V, Corse A, Mosmiller B, Kelley A, Ho D, Srinivasan J, Vytopil M, Jara J, Ventura N, Carter C, Donahue C, Herbert C, Scala S, Weiner E, Alam S, McKinnon J, Haar L, McKinnon N, Alcon K, McKenna K, Sattar N, Daniels K, Jeffery D, Freimer M, Hoyle J, Kissel J, Agriesti J, Chelnick S, Mezache L, Pineda C, Muharrem F, Karam C, Khoury J, Marburger T, Kaur H, Dimitrova D, Gilchrist J, Agrawal B, Elsayed M, Kohlrus S, Ardoin A, Darnell T, Golden L, Lokaitis B, Seelbach J, Muppidi S, Goyal N, Sakamuri S, So Y, Paulose S, Pol S, Welsh L, Bhavaraju‐Sanka R, Gonzalez A, Dishman L, Jones F, Gonzalez A, Padilla P, Saklad A, Silva M, Nations S, Trivedi J, Hopkins S, Kazamel M, Alsharabati M, Lu L, Nozaki K, Mumfrey‐Thomas S, Woodall A, Cash T, Goyal N, Roy G, Mathew V, Maqsood F, Minton B, Jones H, Rosenfeld J, Garcia R, Echevarria L, Garcia S, Pulley M, Aranke S, Berger A, Shah J, Shabbir Y, Smith L, Varghese M, Shabbir Y, Gutmann L, Gutmann L, Jerath N, Nance C, Swenson A, Olalde H, Kressin N, Sieren J, Barohn R, Dimachkie M, Glenn M, McVey A, Pasnoor M, Statland J, Wang Y, Liu T, Emmons K, Jenci N, Locheke J, Fondaw A, Johns K, Rico G, Walsh M, Herbelin L, Hafer‐Macko C, Kwan J, Zilliox L, Callison K, Young V, DiSanzo B, Naunton K, Benatar M, Bilsker M, Sharma K, Cooley A, Reyes E, Michon S, Sheldon D, Steele J, Howard J, Karam C, Traub R, Chopra M, Vu T, Katzin L, McClain T, Harvey B, Hart A, Huynh K, Beydoun S, Chilingaryan A, Doan V, Droker B, Gong H, Karimi S, Lin F, McClain T, Polaka K, Shah A, Tran A, Akhter S, Malekniazi A, Tandan R, Hehir M, Waheed W, Lucy S, Weiss M, Distad J, Strom S, Downing S, Kim B, Bertorini T, Arnold T, Henderson K, Pillai R, Liu Y, Wheeler L, Hewlett J, Vanderhook M, Dicapua D, Keung B, Kumar A, Patwa H, Robeson K, Yang I, Nye J, Vu H. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle & Nerve 2021, 64: 662-669. PMID: 34590717, DOI: 10.1002/mus.27422.Peer-Reviewed Original ResearchConceptsRituximab useMyasthenia gravisSubgroup analysisAmerica Post-Intervention StatusMyasthenia Gravis ActivitiesSafety of eculizumabOpen-label extensionMyasthenia Gravis FoundationUnmet treatment needDaily living (IADL) total scorePost-intervention statusEculizumab treatmentWeek 130Rituximab treatmentBaseline characteristicsMost patientsPersistent symptomsSafety profileEffective therapyTreatment needsEculizumabMinimal manifestationsExtension studyREGAIN studyPatientsImmuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2
Chun HJ, Coutavas E, Pine AB, Lee AI, Yu VL, Shallow MK, Giovacchini CX, Mathews AM, Stephenson B, Que LG, Lee PJ, Kraft BD. Immuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2. JCI Insight 2021, 6: e148476. PMID: 34111030, PMCID: PMC8410030, DOI: 10.1172/jci.insight.148476.Peer-Reviewed Original ResearchConceptsCOVID-19 severityIntensive care unitCOVID-19 illnessRespiratory symptomsLipocalin-2Acute COVID-19 illnessSARS-CoV-2 infectionCOVID-19Acute COVID-19Mild COVID-19Prospective cohort studyPulmonary function testsPost-acute sequelaeAmerican Heart AssociationHost response profileSeparate validation cohortAcademic medical centerSARS-CoV-2Plasma biomarker profilesICU groupLung recoveryCohort studyExpiratory volumeLung impairmentPersistent symptomsClinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY
Walker AJ, MacKenna B, Inglesby P, Tomlinson L, Rentsch CT, Curtis HJ, Morton CE, Morley J, Mehrkar A, Bacon S, Hickman G, Bates C, Croker R, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Williamson EJ, Hulme WJ, McDonald HI, Mathur R, Eggo RM, Wing K, Wong AY, Forbes H, Tazare J, Parry J, Hester F, Harper S, O’Hanlon S, Eavis A, Jarvis R, Avramov D, Griffiths P, Fowles A, Parkes N, Douglas IJ, Evans SJ, Smeeth L, Goldacre B, . Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. British Journal Of General Practice 2021, 71: bjgp.2021.0301. PMID: 34340970, PMCID: PMC8340730, DOI: 10.3399/bjgp.2021.0301.Peer-Reviewed Original ResearchConceptsLong COVIDEnglish primary carePrimary careDiagnostic codesPopulation-based cohort studyAcute COVID-19Different diagnostic thresholdsProportion of peoplePlanning of servicesPersistent symptomsCohort studyGeneral practiceClinicians' understandingDiagnostic thresholdNHS EnglandPatient recordsClinical codesClinical codingCareCOVID-19East of EnglandPatientsDemographic factorsCOVIDWeeksPost-acute COVID-19 syndrome
Nalbandian A, Sehgal K, Gupta A, Madhavan M, McGroder C, Stevens J, Cook J, Nordvig A, Shalev D, Sehrawat T, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner G, Bernstein E, Mohan S, Beckley A, Seres D, Choueiri T, Uriel N, Ausiello J, Accili D, Freedberg D, Baldwin M, Schwartz A, Brodie D, Garcia C, Elkind M, Connors J, Bilezikian J, Landry D, Wan E. Post-acute COVID-19 syndrome. Nature Medicine 2021, 27: 601-615. PMID: 33753937, PMCID: PMC8893149, DOI: 10.1038/s41591-021-01283-z.Peer-Reviewed Original ResearchConceptsPost-acute COVID-19COVID-19Post-acute COVID-19 syndromeSevere acute respiratory syndrome coronavirus 2Dedicated COVID-19 clinicsAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Organ-specific sequelaeAcute COVID-19Long-term complicationsMulti-organ diseaseOnset of symptomsPopulation of patientsCOVID-19 syndromeCOVID-19 survivorsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 clinicSyndrome coronavirus 2Disease 2019 pandemicPatient advocacy groupsGlobal healthcare crisisViral syndromePersistent symptomsMultidisciplinary careCoronavirus 2
2020
A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future
Lutchmansingh DD, Knauert MP, Antin-Ozerkis DE, Chupp G, Cohn L, Dela Cruz CS, Ferrante LE, Herzog EL, Koff J, Rochester CL, Ryu C, Singh I, Tickoo M, Winks V, Gulati M, Possick JD. A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future. CHEST Journal 2020, 159: 949-958. PMID: 33159907, PMCID: PMC7641526, DOI: 10.1016/j.chest.2020.10.067.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute diseaseRespiratory syndromeSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Post-intensive care syndromePotential long-term complicationsCOVID-19Respiratory syndrome coronavirus 2Middle East respiratory syndromeSevere acute respiratory syndromeCoronavirus disease 2019 (COVID-19) casesPersistent respiratory symptomsLong-term complicationsCOVID-19 survivorsSyndrome coronavirus 2Acute respiratory syndromeCOVID-19 outcomesChronic complicationsPersistent symptomsRespiratory symptomsCoronavirus 2Lung diseaseNonhospitalized individualsClinical programsComplications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply